• Careers
  • Investors
  • News
  • Partnering
  • Contact Us
 
  • Home
  • Our Products
    • Recent Products
    • Consumer Products
    • Medical Devices & Diagnostics
    • Prescription Products
    • Product Coupons
  • Our Caring
    • Our Stories
    • Our Giving
    • Our Responsibility
    • Protecting Our People
    • Company Initiatives
  • Our Company
    • Our Credo Values
    • Our Management Approach
    • Our Citizenship
    • Corporate Governance
    • Company Structure
    • Our People & Diversity
    • Company Publications
    • Our History
  • News
    • All News
    • Corporate News
    • Product And Operating Company News
    • Financial News
    • Media Contacts
    • All News Archive
  • Text Size
  • Text Only
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | .... 39 Next >
Johnson & Johnson Reports 2012 Second-Quarter Results

July 17, 2012

Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis

July 16, 2012

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2012

July 16, 2012

Janssen Research & Development, LLC, Sponsors First of its Kind Research Initiative to Advance Multiple Sclerosis Science

July 10, 2012

Janssen Licenses Diabetes Research Programs From Evotec and Harvard University

July 10, 2012

U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE

July 09, 2012

< Prev | | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Employees
  • Careers
  • Investors
  • News
  • Partnering
  • Contact Us
Johnson & Johnson
  • Home
  • Our Products
  • Our Caring
  • Our Company
  • All News
  • Corporate News
  • Product And Operating Company News
  • Financial News
  • Media Contacts
  • All News Archive
  • Text Size
  • Graphic Version
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | .... 39 Next >
Johnson & Johnson Reports 2012 Second-Quarter Results

July 17, 2012

Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis

July 16, 2012

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2012

July 16, 2012

Janssen Research & Development, LLC, Sponsors First of its Kind Research Initiative to Advance Multiple Sclerosis Science

July 10, 2012

Janssen Licenses Diabetes Research Programs From Evotec and Harvard University

July 10, 2012

U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE

July 09, 2012

< Prev | | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •